{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:54:31Z","timestamp":1781661271071,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Chronic subdural hematoma (CSDH) is a prevalent neurosurgical disorder with high clinical morbidity, particularly in the elderly, and conventional treatments are plagued by high recurrence rates and perioperative complications. This study aimed to rigorously evaluate the short- and mid-term efficacy and safety of standalone middle meningeal artery (MMA) embolization as a first-line minimally invasive treatment for CSDH patients who are intolerant to conventional surgical interventions.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective cohort study was conducted on consecutively screened patients with CSDH who underwent standalone MMA embolization at a tertiary academic hospital between January 2020 and December 2025. Strict and quantified inclusion and exclusion criteria were applied to ensure cohort homogeneity. The embolization technique was standardized with Onyx 18 as the exclusive embolic agent. Primary outcomes included hematoma resolution rate, complete hematoma absorption rate, and hematoma recurrence rate at 3, 6, and 12 months of follow-up (all patients completed 12-month scheduled follow-up). Secondary outcomes comprised neurological functional recovery (modified Rankin Scale, mRS), midline shift improvement, and procedure-related complications (graded by the Clavien-Dindo classification). Hematoma volume was calculated using the ellipsoid formula, and linear regression analysis was performed to explore the correlation between initial hematoma volume and time to complete absorption (as an exploratory analysis).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 85 patients with 99 CSDHs (14 bilateral cases) were enrolled, accounting for 18.6% of the total CSDH patients admitted to our hospital during the same period, with a mean age of 63.6\u2009\u00b1\u20099.2 years (32 patients\u2009\u2265\u200970 years, 37.6%). All MMA embolization procedures achieved 100% technical success with no intraprocedural conversion to open surgery. At the 12-month follow-up, the mean hematoma volume was significantly reduced from a baseline of 59.4\u2009\u00b1\u200921.8 mL to 4.1\u2009\u00b1\u20098.7 mL (\n P<\/jats:italic>\n \u2009<\u20090.001, 95% CI: 51.2\u201359.9), and the mean midline shift was completely resolved from 2.0\u2009\u00b1\u20092.9\u00a0mm to 0\u00a0mm (\n P<\/jats:italic>\n \u2009<\u20090.001, 95% CI: 1.4\u20132.6). The complete hematoma absorption rates were 42.4% (95% CI: 32.9\u201352.4), 75.8% (95% CI: 66.8\u201383.2), and 80.8% (95% CI: 72.2\u201387.4) at 3, 6, and 12 months, respectively, with a mean hematoma resolution rate of 1.84\u2009\u00b1\u20090.69 days per milliliter (95% CI: 1.69\u20131.99); a strong positive linear correlation was observed between initial hematoma volume and time to complete absorption in CSDHs with complete resolution (R\u00b2=0.90,\n P<\/jats:italic>\n \u2009<\u20090.001), which reflects limited variability in this homogeneous subgroup rather than generalizable predictive power. Neurological function was significantly improved (\n P<\/jats:italic>\n \u2009<\u20090.001, Wilcoxon signed-rank test), with 70.6% (95% CI: 59.7\u201379.5) of patients achieving mRS 0 and 29.4% (95% CI: 20.5\u201340.3) achieving mRS 1 at 12 months (no patients with mRS\u2009\u2265\u20092). No severe procedure-related complications (Clavien-Dindo\u2009\u2265\u2009II) were observed; only 26 patients reported mild postoperative headache, which resolved with conservative management within 3 days. Hematoma density (hypodense\/mixed\/hyperdense) was not associated with hematoma absorption outcomes (\n P<\/jats:italic>\n \u2009>\u20090.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Standalone MMA embolization with Onyx 18 is a safe and effective minimally invasive treatment for CSDH patients who are intolerant to conventional surgical interventions, yielding a 0% mid-term recurrence rate, significant hematoma resolution, and excellent neurological functional recovery in the selected cohort. This technique represents a promising alternative to conventional surgical interventions for the above-mentioned patient population. The linear correlation between initial hematoma volume and time to complete absorption provides a single-center exploratory quantitative tool for personalized patient follow-up, and its clinical value needs to be verified in multi-center cohorts.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n The study was approved by the Institutional Review Board (IRB) of Sir Run Run Shaw Hospital.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s12883-026-04933-2","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:08:30Z","timestamp":1777529310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of standalone middle meningeal artery embolization for chronic subdural hematoma: a single-center retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Dajiang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"4933_CR1","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1136\/neurintsurg-2020-016552","volume":"12","author":"JS Catapano","year":"2020","unstructured":"Catapano JS, Ducruet AF, Nguyen CL, et al. Middle meningeal artery embolization for chronic subdural hematoma: an institutional technical analysis. J Neurointerv Surg. 2020;12:1196\u2013200. https:\/\/doi.org\/10.1136\/neurintsurg-2020-016552.","journal-title":"J Neurointerv Surg"},{"key":"4933_CR2","doi-asserted-by":"publisher","first-page":"557233","DOI":"10.3389\/fneur.2020.557233","volume":"11","author":"JS Catapano","year":"2020","unstructured":"Catapano JS, Nguyen CL, Wakim AA, et al. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma. Front Neurol. 2020;11:557233. https:\/\/doi.org\/10.3389\/fneur.2020.557233.","journal-title":"Front Neurol"},{"key":"4933_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/neuros\/nyaa379","volume":"89","author":"P Kan","year":"2021","unstructured":"Kan P, Maragkos GA, Srivatsan A, et al. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Multi-Center Experience of 154 Consecutive Embolizations. Neurosurgery. 2021;89:268\u201377. https:\/\/doi.org\/10.1093\/neuros\/nyaa379.","journal-title":"Neurosurgery"},{"key":"4933_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/neurintsurg-2021-017352","volume":"13","author":"N Ironside","year":"2021","unstructured":"Ironside N, Nguyen C, Do Q, et al. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis. J Neurointerv Surg. 2021;13:951\u20137. https:\/\/doi.org\/10.1136\/neurintsurg-2021-017352.","journal-title":"J Neurointerv Surg"},{"key":"4933_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.wneu.2021.12.080","volume":"159","author":"M Abdalkader","year":"2022","unstructured":"Abdalkader M, Nguyen TN. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma. World Neurosurg. 2022;159:80\u20132. https:\/\/doi.org\/10.1016\/j.wneu.2021.12.080.","journal-title":"World Neurosurg"},{"key":"4933_CR6","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/neurintsurg-2019-014730","volume":"11","author":"D Fiorella","year":"2019","unstructured":"Fiorella D, Arthur AS. Middle meningeal artery embolization for the management of chronic subdural hematoma. J Neurointerv Surg. 2019;11:912\u20135. https:\/\/doi.org\/10.1136\/neurintsurg-2019-014730.","journal-title":"J Neurointerv Surg"},{"key":"4933_CR7","doi-asserted-by":"publisher","first-page":"e222045","DOI":"10.1148\/radiol.222045","volume":"307","author":"MM Salem","year":"2023","unstructured":"Salem MM, Kuybu O, Nguyen Hoang A, et al. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Predictors of Clinical and Radiographic Failure from 636 Embolizations. Radiology. 2023;307:e222045. https:\/\/doi.org\/10.1148\/radiol.222045.","journal-title":"Radiology"},{"key":"4933_CR8","doi-asserted-by":"publisher","first-page":"e230158","DOI":"10.1148\/rg.230158","volume":"44","author":"\u00c1H Schmolling","year":"2024","unstructured":"Schmolling \u00c1H, P\u00e9rez-Garc\u00eda C, Trejo C, et al. Middle Meningeal Artery Embolization for Management of Chronic Subdural Hematoma. Radiographics. 2024;44:e230158. https:\/\/doi.org\/10.1148\/rg.230158.","journal-title":"Radiographics"},{"key":"4933_CR9","doi-asserted-by":"publisher","first-page":"1222131","DOI":"10.3389\/fneur.2023.1222131","volume":"14","author":"A Orscelik","year":"2024","unstructured":"Orscelik A, Senol YC, Bilgin C, et al. Middle meningeal artery embolization without surgical evacuation for chronic subdural hematoma: a single-center experience of 209 cases. Front Neurol. 2024;14:1222131. https:\/\/doi.org\/10.3389\/fneur.2023.1222131.","journal-title":"Front Neurol"},{"key":"4933_CR10","doi-asserted-by":"publisher","first-page":"e230405","DOI":"10.1148\/radiol.230405","volume":"307","author":"N Chaudhary","year":"2023","unstructured":"Chaudhary N, Gemmete JJ. Insights into Middle Meningeal Artery Embolization in Chronic Subdural Hematoma: What Does Not Work. Radiology. 2023;307:e230405. https:\/\/doi.org\/10.1148\/radiol.230405.","journal-title":"Radiology"},{"issue":"Suppl 1","key":"4933_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00117-022-01074-8","volume":"62","author":"R M\u00fchl-Benninghaus","year":"2022","unstructured":"M\u00fchl-Benninghaus R. Middle meningeal artery embolization for treatment of chronic subdural hematoma. Radiol (Heidelb). 2022;62(Suppl 1):17\u201321. https:\/\/doi.org\/10.1007\/s00117-022-01074-8.","journal-title":"Radiol (Heidelb)"},{"key":"4933_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.06934.92","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.06934.92.","journal-title":"Ann Surg"},{"issue":"20","key":"4933_CR13","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa2402645","volume":"391","author":"D Fiorella","year":"2024","unstructured":"Fiorella D, Meyers PM, Jahan R, et al. Middle Meningeal Artery Embolization plus Burr-Hole Drainage for Chronic Subdural Hematoma. N Engl J Med. 2024;391(20):1897\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2402645.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"4933_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/cjn.2023.249","volume":"50","author":"S Jai","year":"2023","unstructured":"Jai S, Zul K. Grading Embolization of Middle Meningeal Artery for Chronic Subdural Hematoma. Can J Neurol Sci. 2023;50(Suppl 1):1\u20135. https:\/\/doi.org\/10.1017\/cjn.2023.249.","journal-title":"Can J Neurol Sci"},{"key":"4933_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/15910199221091896","volume":"28","author":"W Brinjikji","year":"2022","unstructured":"Brinjikji W. Particle theory in middle meningeal artery embolization for chronic subdural hematoma. Interv Neuroradiol. 2022;28:131\u20133. https:\/\/doi.org\/10.1177\/15910199221091896.","journal-title":"Interv Neuroradiol"},{"key":"4933_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jocn.2023.10.028","volume":"121","author":"HS Kim","year":"2024","unstructured":"Kim HS, Kim JH, Park JH, et al. Comparison of Onyx and PVA particles for middle meningeal artery embolization in chronic subdural hematoma: a retrospective cohort study. J Clin Neurosci. 2024;121:108\u201312. https:\/\/doi.org\/10.1016\/j.jocn.2023.10.028.","journal-title":"J Clin Neurosci"},{"key":"4933_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12974-022-02638-9","volume":"19","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li X, Wang H, et al. Inflammatory mechanisms in chronic subdural hematoma: a systematic review. J Neuroinflammation. 2022;19:214. https:\/\/doi.org\/10.1186\/s12974-022-02638-9.","journal-title":"J Neuroinflammation"},{"key":"4933_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3174\/ajnr.A7962","volume":"44","author":"SY Park","year":"2023","unstructured":"Park SY, Kim BK, Lee JH, et al. Risk factors for recurrence after middle meningeal artery embolization for chronic subdural hematoma. AJNR Am J Neuroradiol. 2023;44:1123\u20138. https:\/\/doi.org\/10.3174\/ajnr.A7962.","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04933-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04933-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04933-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:20:08Z","timestamp":1781659208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04933-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4933"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04933-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. Owing to the retrospective design and use of fully anonymized patient data, informed consent was waived in compliance with the Declaration of Helsinki (2024 revision). No additional interventions were performed, and all analyses used de-identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"393"}}